Inflammatory cytokines in diabetic retinopathy
糖尿病视网膜病变中的炎症细胞因子
基本信息
- 批准号:7195015
- 负责人:
- 金额:$ 42.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-04-01 至 2010-03-31
- 项目状态:已结题
- 来源:
- 关键词:Acute-Phase ProteinsAcute-Phase ReactionAdultAffectApoptosisAtherosclerosisBlindnessBloodBlood VesselsCell Adhesion MoleculesCell CommunicationCellsClinicalComplementComplications of Diabetes MellitusConditioned Culture MediaCultured CellsDepositionDevelopmentDiabetes MellitusDiabetic RetinopathyDiseaseEndothelial CellsEnzyme-Linked Immunosorbent AssayFunctional disorderGene TransferGlial Fibrillary Acidic ProteinGlucoseHumanImmunohistochemistryIn Situ HybridizationIn VitroInflammatoryInflammatory ResponseIntercellular adhesion molecule 1Interleukin-1 ReceptorsInterleukinsLabelMeasuresMediator of activation proteinModelingMuller&aposs cellNeurogliaPharmaceutical PreparationsPlayPopulationPreventionProductionProtein OverexpressionProteinsReceptor SignalingRecombinantsResearchResearch PersonnelRetinaRetinalRetinal DiseasesRheumatoid ArthritisRoleSignal TransductionSourceSystemUnited StatesUp-RegulationViral Vectoranakinracell typecytokinediabeticdiabetic ratinhibitor/antagonistinterleukin-1 receptor type IIneuron apoptosispreventprogramsreceptorrelating to nervous systemresearch studyretinal damagetool
项目摘要
DESCRIPTION (provided by applicant): Diabetic retinopathy is the leading cause of blindness in the US adult population. To develop, effective approaches to prevent this disease, there is a crucial need for a better understanding of the mechanisms of diabetes-induced retinal damage. We have recently found that glial Muller cells mount an acute-phase response in diabetes, which is accompanied by retinal induction of the inflammatory cytokine interleukin 1¿ (IL-1¿). In this project, we intend to investigate the hypothesis that IL-1¿ upregulation contributes to the glial and vascular abnormalities of the diabetic retina. The specific aims are: 1. To identify the cell type/s that upregulate IL-1¿ and characterize the IL-1¿ system in the diabetic retina. The retinal cell type/s expressing IL-1¿ in diabetes will be identified by in situ hybridization and immunohistochemistry. To investigate the effect of diabetes on the IL-1¿ system, we will study the retinal expression and cellular distribution of the two IL-1¿ endogenous inhibitors - decoy receptor IL-1RII and receptor antagonist IL-1ra - and of the two components of the IL-1¿ signaling receptor - IL-1RI and IL-1RAcP. 2. To determine the mechanisms and consequences of IL-1¿ upregulation in retinal cells. We will perform in vitro studies to determine whether high glucose upregulates IL-1¿ in cell culture models. We will then investigate whether IL-1¿ is sufficient to mimic the effect of diabetes on Muller cells, and the interaction of IL-1¿ with other diabetes-induced factors. 3. To determine whether inhibition of IL-1¿ activity can prevent the development of diabetic retinopathy. As conclusive evidence for a role of IL-1¿ in diabetic retinopathy, we will evaluate the effect of retinal overexpression of IL-1ra in preventing retinal abnormalities in diabetic rats. Identifying IL-1¿ as a mediator of diabetes-induced retinal damage would open new avenues for the prevention of retinopathy. Recombinant IL-1ra or other anti-IL-1¿ drugs could become powerful tools to prevent retinopathy - with possible applications to other diabetic complications with an inflammatory component such as atherosclerosis.
描述(由申请人提供):糖尿病视网膜病变是美国成年人群失明的主要原因。为了开发有效的方法来预防这种疾病,迫切需要更好地了解糖尿病引起的视网膜损伤的机制。我们最近发现,神经胶质Muller细胞在糖尿病中出现急性期反应,伴随着视网膜诱导炎症细胞因子白细胞介素1 <$(IL-1 <$)。在这个项目中,我们打算调查的假设,IL-1上调有助于神经胶质和血管异常的糖尿病视网膜。具体目标是:1.确定上调IL-1 <$的细胞类型并表征糖尿病视网膜中的IL-1 <$系统。将通过原位杂交和免疫组织化学鉴定糖尿病中表达IL-1的视网膜细胞类型。为了研究糖尿病对IL-1 <$系统的影响,我们将研究两种IL-1 <$内源性抑制剂-诱饵受体IL-1 RII和受体拮抗剂IL-1 ra-以及IL-1 <$信号受体的两种组分- IL-1 RI和IL-1 RAcP的视网膜表达和细胞分布。2.确定视网膜细胞中IL-1上调的机制和后果。我们将进行体外研究,以确定高葡萄糖是否在细胞培养模型中上调IL-1?。然后,我们将研究IL-1 <$是否足以模拟糖尿病对Muller细胞的影响,以及IL-1 <$与其他糖尿病诱导因子的相互作用。3.确定抑制IL-1活性是否可以预防糖尿病视网膜病变的发展。作为IL-1在糖尿病视网膜病变中作用的确凿证据,我们将评估视网膜过表达IL-1 ra在预防糖尿病大鼠视网膜异常中的作用。确定IL-1作为糖尿病诱导的视网膜损伤的介质将为预防视网膜病变开辟新的途径。重组IL-1 ra或其他抗IL-1药物可能成为预防视网膜病变的有力工具-可能应用于其他具有炎症成分的糖尿病并发症,如动脉粥样硬化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHIARA GERHARDINGER其他文献
CHIARA GERHARDINGER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHIARA GERHARDINGER', 18)}}的其他基金
Mechanisms of action of drugs that prevent experimental diabetic retinopathy
预防实验性糖尿病视网膜病变药物的作用机制
- 批准号:
8007361 - 财政年份:2009
- 资助金额:
$ 42.82万 - 项目类别:
Mechanisms of action of drugs that prevent experimental diabetic retinopathy
预防实验性糖尿病视网膜病变药物的作用机制
- 批准号:
8207291 - 财政年份:2009
- 资助金额:
$ 42.82万 - 项目类别:
Mechanisms of action of drugs that prevent experimental diabetic retinopathy
预防实验性糖尿病视网膜病变药物的作用机制
- 批准号:
7751234 - 财政年份:2009
- 资助金额:
$ 42.82万 - 项目类别:
Mechanisms of action of drugs that prevent experimental diabetic retinopathy
预防实验性糖尿病视网膜病变药物的作用机制
- 批准号:
7582470 - 财政年份:2009
- 资助金额:
$ 42.82万 - 项目类别:
Mechanisms of action of drugs that prevent experimental diabetic retinopathy
预防实验性糖尿病视网膜病变药物的作用机制
- 批准号:
8004774 - 财政年份:2009
- 资助金额:
$ 42.82万 - 项目类别:
Inflammatory cytokines in diabetic retinopathy
糖尿病视网膜病变中的炎症细胞因子
- 批准号:
7386653 - 财政年份:2006
- 资助金额:
$ 42.82万 - 项目类别:
Inflammatory cytokines in diabetic retinopathy
糖尿病视网膜病变中的炎症细胞因子
- 批准号:
7096971 - 财政年份:2006
- 资助金额:
$ 42.82万 - 项目类别:
Inflammatory cytokines in diabetic retinopathy
糖尿病视网膜病变中的炎症细胞因子
- 批准号:
7599530 - 财政年份:2006
- 资助金额:
$ 42.82万 - 项目类别:
相似海外基金
Modulation of hepatic acute phase reaction and antiviral response by pro-apaptotic substances (B13)
促凋亡物质调节肝脏急性期反应和抗病毒反应(B13)
- 批准号:
57771341 - 财政年份:2008
- 资助金额:
$ 42.82万 - 项目类别:
Collaborative Research Centres
Effect of abnormal body temperature on ventilator induced lung injury and acute phase reaction
体温异常对呼吸机所致肺损伤及急性时相反应的影响
- 批准号:
18591710 - 财政年份:2006
- 资助金额:
$ 42.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
gp130-dependent acute phase reaction: new therapeutical strategies to prevent vascular diseases (B 09)
gp130依赖性急性期反应:预防血管疾病的新治疗策略(B 09)
- 批准号:
5274832 - 财政年份:2001
- 资助金额:
$ 42.82万 - 项目类别:
Collaborative Research Centres
NEUROPEPTIDERGIC MEDIATION OF THE ACUTE PHASE REACTION
急性期反应的神经肽能介导
- 批准号:
3477337 - 财政年份:1988
- 资助金额:
$ 42.82万 - 项目类别:
NEUROPEPTIDERGIC MEDIATION OF THE ACUTE PHASE REACTION
急性期反应的神经肽能介导
- 批准号:
3477338 - 财政年份:1988
- 资助金额:
$ 42.82万 - 项目类别:
NEUROPEPTIDERGIC MEDIATION OF THE ACUTE PHASE REACTION
急性期反应的神经肽能介导
- 批准号:
3477340 - 财政年份:1988
- 资助金额:
$ 42.82万 - 项目类别:
NEUROPEPTIDERGIC MEDIATION OF THE ACUTE PHASE REACTION
急性期反应的神经肽能介导
- 批准号:
3477339 - 财政年份:1988
- 资助金额:
$ 42.82万 - 项目类别:
NEUROPEPTIDERGIC MEDIATION OF THE ACUTE PHASE REACTION
急性期反应的神经肽能介导
- 批准号:
3477341 - 财政年份:1988
- 资助金额:
$ 42.82万 - 项目类别:
CENTRAL MONOAMINES AND OPIOIDS IN ACUTE-PHASE REACTION
急性期反应中的中心单胺和阿片类药物
- 批准号:
3405544 - 财政年份:1986
- 资助金额:
$ 42.82万 - 项目类别:














{{item.name}}会员




